logo
Plus   Neg
Share
Email

BridgeBio Pharma To Make Stock Exchange Debut Today

nasdaq-jun27-lt.jpg

Shares of BridgeBio Pharma Inc. are expected to begin trading on the Nasdaq Global Select Market today (June 27, 2019), under the ticker symbol "BBIO".

The Company has priced its initial public offering of 20.50 million shares of its common stock at $17.00 per share, above the previously announced range of $14.00 to $16.00.

The offering is expected to close on July 1, 2019, subject to customary closing conditions. The underwriters have a 30-day option to purchase up to 3.10 million additional shares of the Company's common stock.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC, SVB Leerink LLC, KKR Capital Markets LLC, Piper Jaffray & Co., Mizuho Securities USA LLC, BMO Capital Markets Corp. and Raymond James & Associates, Inc. are acting as book-running managers for the offering.

The Company and its People:

Founded in 2015, Palo Alto, California-based BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on developing breakthrough medicines for genetic diseases.

Neil Kumar is the CEO and co-founder of BridgeBio Pharma. Brian Stephenson serves as the Company's CFO, and Uma Sinha is its Chief Scientific Officer.

Pipeline:

The Company has four product candidates in clinical trials, and a couple of compounds in early stages of development.

-- BBP-870 for treatment of molybdenum cofactor deficiency type A, for which the Company expects to initiate the submission of a rolling NDA seeking regulatory approval in the United States in 2019, based on existing safety and efficacy data.

-- BBP-265 that is in an ongoing Phase 3 clinical trial for the treatment of Transthyretin Amyloidosis Cardiomyopathy, dubbed ATTRibute-CM.

-- BBP-009 for treatment of nevoid basal cell carcinoma syndrome, or Gorlin syndrome, which is under phase III development.

-- BBP-831/Infigratinib, a phase III-ready compound for the treatment of FGFR-driven cancers. It is also in preclinical development for the treatment of achondroplasia.

-- BBP-631, a preclinical adeno-associated virus, or AAV, gene transfer product candidate, for the treatment of Congenital Adrenal Hyperplasia.

-- BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers.

Near-term Catalysts:

-- A phase III trial of BBP-265 in Transthyretin Amyloid Polyneuropathy is expected to be initiated this year.
-- Data from phase II open-label extension study of BBP-265 in Transthyretin Amyloidosis Cardiomyopathy is expected in 2019.
-- The first patient in phase III clinical trial of BBP-831 in advanced cholangiocarcinoma as a first-line therapy is anticipated to be enrolled this year.
-- A phase III clinical trial of BBP-831 in adjuvant urothelial carcinoma is expected to be initiated this year.
-- IND submission and initiation of phase I/II clinical trial of BBP-831 in achondroplasia is expected in 2020.

Related link

Biotech IPOs For The Week Ahead

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>